Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas

Oncogene

Volumn 26, Issue 2, 2007, Pages 277-283

  Mathur, M ^a   Samuels, H H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Dedifferentiation; Growth inhibition; PSF TFE3; siRNA; Transformation

Indexed keywords

ONCOPROTEIN; ONCOPROTEIN PSF TFE3; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL DAMAGE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EPITHELIAL CELLS; HUMANS; KIDNEY NEOPLASMS; KIDNEY TUBULES, PROXIMAL; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 33846214715     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209783     Document Type: Article

References (25)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM et al. (1987). Cancer Res 47: 3239-3245.
2. Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R et al. (2001). Am J Pathol 159: 179-192.
3. Argani P, Lui MY, Couturier J, Bouvier R, Fournet JC, Ladanyi M. (2003). Oncogene 22: 5374-5378.
4. Bennicelli JL, Barr FG. (2002). Curr Opin Oncol 14: 412-419.
5. Bissell MJ, Radisky D. (2001). Nat Rev Cancer 1: 46-54.
6. Bodmer D, Van Den Hurk W, Van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA et al. (2002). Hum Mol Genet 11: 2489-2498.
7. Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M et al. (2005). Proc Natl Acad Sci USA 102: 10528-10533.
8. Guo HF, Gong K, Zou SM, Zhang ZW, Liu XY, Na X et al. (2004). Zhonghua Wai Ke Za Zhi 42: 196-200.
9. Kolb RJ, Woost PG, Hopfer U. (2004). Hypertension 44: 352-359.
10. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B et al. (1997). J Pathol 183: 131-133.
11. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P et al. (2001). Oncogene 20: 48-57.
12. Le TH, Oliverio MI, Kim HS, Salzler H, Dash RC, Howell DN et al. (2004). Physiol Genom 18: 290-298.
13. Lindor NM, Dechet CB, Greene MH, Jenkins RB, Zincke MT, Weaver AL et al. (2001). Genet Test 5: 101-106.
14. Mathur M, Das S, Samuels HH. (2003). Oncogene 22: 5031-5044.
15. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D et al. (2001). Cancer Res 61: 7277-7281.
16. Murer H, Hernando N, Forster I, Biber J. (2000). Physiol Rev 80: 1373-1409.
17. Orosz DE, Woost PG, Kolb RJ, Finesilver MB, Jin W, Frisa PS et al. (2004). In vitro Cell Dev Biol Anim 40: 22-34.
18. Radisky D, Hagios C, Bissell MJ. (2001). Semin Cancer Biol 11: 87-95.
19. Sanders ME, Mick R, Tomaszewski JE, Barr FG. (2002). Am J Pathol 161: 997-1005.
20. Skalsky YM, Ajuh PM, Parker C, Lamond AI, Goodwin G, Cooper CS. (2001). Oncogene 20: 178-187.
21. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG et al. (1997). Cancer 80: 987-989.
22. Weterman MA, van Groningen JJ, den Hartog A, Geurts van Kessel A. (2001a). Oncogene 20: 1414-1424.
23. Weterman MA, van Groningen JJ, Tertoolen L, van Kessel AG. (2001b). Proc Natl Acad Sci USA 98: 13808-13813.
24. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A et al. (2001). Cancer Res 61: 5215-5222.
25. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al. (2003). N Engl J Med 349: 427-434.